

4. The method of claim 3, wherein said flat worm is a trematode.
5. The method of claim 4, wherein said trematode is a schistosome.
6. The method of claim 5, wherein said developmental stage is miracidia, either within ova or after hatching.
7. The method of claim 1, wherein the parasite is infective to human or animal.
8. The method of claim 1, wherein the parasite is infective to human.
9. The method of claim 5, wherein said schistosome is infective to human.
10. The method of claim 5, wherein said schistosome is selected from the group consisting of *Schistosoma mansoni*, *Schistosoma haematobium*, *Schistosoma japonicum*, *Schistosoma bovis*, *Schistosoma mattheei*, *Schistosoma rhodhaini*, *Schistosoma magrebowiei*, *Schistosoma intercalatum*, *Schistosoma curasoni*, *Schistosoma mekongi*, *Schistosoma spindale*, *Schistosoma leipere*, *Schistosoma turkestanicum*, *Schistosoma inidicum*, *Schistosoma nasalis* and *Schistosoma suis*.
11. The method of claim 1, wherein the parasite is sensitive to a known drug.
12. The method of claim 1, wherein said group transformation method is selected from the group consisting of electroporation, chemical transformation, lipofection and biolistic bombardment.
13. The method of claim 1, wherein said transgene is integrated in the parasite genome.
14. The method of claim 1, wherein said transgene is integrated in a selected genomic locus in the parasite genome.
15. The method of claim 14, wherein said selected genomic locus is a repetitive sequence.



Date: May 29, 2001